Precision therapy for solid tumors targeting CDK4/6 and VEGF
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a combination of two targeted drugs for advanced solid tumors like colorectal, lung, breast, and genitourinary cancers. The goal is to see if blocking certain proteins and a long RNA molecule can slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be of white ethnicity.
- You must be at least 18 years old.
- You must have a diagnosis of colorectal, lung, genitourinary, or breast cancer that is stage III or IV (with or without spread to lymph nodes or distant organs).
- You cannot have a history of other cancers that have come back or spread.
- You cannot have certain health conditions like inflammatory bowel disease, heart disease, autoimmune disease, diabetes, high blood pressure, neurological disorders, active infections, or a body mass index (BMI) over 30.
- You must not be pregnant or have had significant weight loss or surgeries recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses genetic testing of your tumor to match you with a targeted therapy. It is for people with advanced solid tumors who have exhausted or cannot tolerate standard treatments.
This trial is testing a new oral medication, VVD-133214, for people with advanced solid tumors that have a specific genetic feature called MSI-high or dMMR. The study will see if the drug is safe and effective when given alone or with other drugs like bevacizumab or pembrolizumab.
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
This trial tests a new combination of drugs for advanced solid tumors. It may help if your cancer has not responded to other treatments, and the goal is to see how safe and effective this new approach is.
This Phase 2 study tests treatments guided by blood testing (“liquid biopsy”) in people with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed after standard CDK4/6 medicine plus hormone therapy. It aims to find a better way to control cancer after the first treatment stops working.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.